dr. finn on the rationale for the phase iii keynote-240 trial in hcc
Published 4 years ago • 127 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
1:38
dr. finn on significance of phase iii findings of lenvatinib in hcc
-
2:56
dr. finn on role of lenvatinib in hcc treatment paradigm
-
1:57
dr. finn on recent advances in the treatment of liver cancer
-
1:45
dr. finn on current and emerging agents in the field of hcc
-
2:08
dr. finn on studies of pembrolizumab in hepatocellular carcinoma
-
2:55
richard s. finn, md, regarding outcomes from keynote 240 in 1st line hcc
-
1:41
dr. richard finn describes the phase iii trial of palbociclib for breast cancer
-
1:34
dr. finn on results of resource study in liver cancer
-
2:24
emerging i-o combination trials in unresectable hcc
-
3:06
dr. finn on tivantinib and regorafenib for the treatment of liver cancer
-
0:50
richard s. finn, md, speculates on the next phase of hcc management and research
-
2:13
richard s. finn, md, offers opinion on the role of frontline atezolizumab bevacizumab in hcc
-
1:53
dr. finn discusses sequencing therapy for hcc
-
1:34
dr. richard finn on the future of palbociclib in breast cancer
-
4:25
imbrave150 in unresectable hcc
-
1:57
dr. kaseb on the progression of hcc research
-
8:01
emerging therapies in advanced hcc
-
5:10
understanding the resorce data in second-line hcc
-
1:01:09
evolutions in hepatocellular carcinoma in the era of covid-19